

REFERENCE

- (1) Helewa A. Epidemiology and Economics of Arthritis. In: Walker JM, editor. Physical Therapy in Arthritis. Philadelphia: W.B.Saunders Company, 1996: 9-18.
- (2) Doherty M. Color Atlas and Text of Osteoarthritis. 1 ed. London: Times Mirror International Publishers Limited, 1994.
- (3) Katzung BG. Examination and Broad Review Pharmacology. Connecticut: Appleton and Lange, 1995.
- (4) Jeenapongsa R, Yoovathaworn K, Sriwatanakul KM, Pongprayoon U, Sriwatanakul K. Anti-inflammatory activity of (E)-1-(3,4-dimethoxyphenyl) butadiene from Zingiber cassumunar Roxb. J Ethnopharmacol 2003; 87(2-3):143-148.
- (5) Hardingham T. Methods in Cartilage Research. London: Academic Press, 1990.
- (6) Thomas N W. Extracellular Matrix. 1 ed. London: Harwood academic publishers, 1996.
- (7) Poole R. Arthritis and allied conditions. London: Lea 2 Fabiger, 1993.
- (8) Plaas AH, West LA, Wong-Palms S, Nelson FR. Glycosaminoglycan sulfation in human osteoarthritis. Disease-related alterations at the non-reducing termini of chondroitin and dermatan sulfate. J Biol Chem 1998; 273(20):12642-12649.
- (9) Ratcliffe A, Tyler J.A, Hardingham T E. Articular cartilage cultured with interleukin 1: Increased release of link protein, hyaluronate-binding region, and other proteoglycan fragments. Biochemical Journal 238, 571-580. 1986.

- (10) Ratcliffe A, Mow V C. Extracellular Matrix. 1 ed. London: Harwood academic publishers, 1996.
- (11) Sandy J.D, Flannery C.R, Neame P .J, Lohmander S.L. The structure of aggrecan fragments in human synovial fluid: evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobulin domain. *Journal of Clinical Investigations* 89, 1512-1516. 1992.
- (12) Champe PC, Harvey RA. Lippincott's Illustrated Reviews. Philadelphia: Lippincott company, 1994.
- (13) Blumenfeld I, Livne E. The role of transforming growth factor (TGF)-beta, insulin-like growth factor (IGF)-1, and interleukin (IL)-1 in osteoarthritis and aging of joints. *Exp Gerontol* 1999; 34(7):821-829.
- (14) Melchiorri C, Meliconi R, Silvestri T. Enhanced and co-ordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. *Arthritis Rheum* 41, 2165-2177. 1998.
- (15) Pelletier JP, Roughley PJ, Dibatista JA. Are cytokines involved in osteoarthritic pathophysiology? *Arthritis Rheum* 20, 2-5. 1991.
- (16) Woessner. Matrix metalloproteinase and their inhibitors in connective tissue remodelling. *FASEB J* 5, 2145-2154. 1991.
- (17) Nagase H. Activation mechanisms of matrix metalloproteinases. *Biological Chemistry* 378, 151-160. 1997.

- (18) Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? *Cell* 1995; 83(6):859-869.
- (19) Dingle JT, Horsfield P, Fell HB, Barratt ME. Breakdown of proteoglycan and collagen induced in pig articular cartilage in organ culture. *Ann Rheum Dis* 1975; 34(4):303-311.
- (20) Lapadula G, Nico B, Cantatore FP, La Canna R, Roncali L, Pipitone V. Early ultrastructural changes of articular cartilage and synovial membrane in experimental vitamin A-induced osteoarthritis. *J Rheumatol* 1995; 22(10):1913-1921.
- (21) Connolly TJ, Clohisy JC, Shilt JS, Bergman KD, Partridge NC, Quinn CO. Retinoic acid stimulates interstitial collagenase messenger ribonucleic acid in osteosarcoma cells. *Endocrinology* 1994; 135(6):2542-2548.
- (22) Mark D S, Zena W. *Guidebook to the Extracellular Matrix, Anchor, and Adhesion Proteins*. 2 ed. New York: Oxford University Press Inc, 1999.
- (23) Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteases and inhibitors in arthritic diseases. *Best Pract Res Clin Rheumatol* 2001; 15(5):805-829.
- (24) Matrix metalloproteinase in arthritic disease. *Arthritis Research* 4(suppl3), s39-s49. 2002.
- (25) Martel-P J, Welsch DJ, Pelletier JP. Metalloproteinase and inhibitors in arthritic diseases. *Best Practic and Research Clinical Rheumatology*. 15[5], 805-829. 2001.
- (26) Campion G, Hardingham T. *Oxford Textbook of Rheumatology*. Oxford: Oxford University Press, 1993.
- (27) Creamer P, Hochberg M. Osteoarthritis (seminar). *Lancet* 350, 503-509. 1997.

- (28) Walker J, Helewa A. Physical therapy in arthritis. Pennsylvania: W.B. Saunders company, 1996.
- (29) Woitge HW, Seibel MJ. Molecular markers of bone and cartilage metabolism. *Curr Opin Rheumatol* 1999; 11(3):218-225.
- (30) Saxne T. Differential release of molecular markers in joint disease. *Acta Orthop Scand Suppl* 1995; 266:80-83.
- (31) Caterson B, Griffin J, Mahmoodian F, Sorrell JM. Monoclonal antibodies against chondroitin sulphate isomers: their use as probes for investigating proteoglycan metabolism. *Biochem Soc Trans* 1990; 18(5):820-823.
- (32) Tiengburanatum N. Production and Characterization of monoclonal antibody against chondroitin 6-sulfate. Chiang Mai University, 1996.
- (33) Caterson B, Hughes CE, Roughley P, Mort JS. Anabolic and catabolic marker of proteoglycan metabolism in osteoarthritis. *Acta Orthop Scand Suppl* 1995; 266:121-124.
- (34) Pothacharoen P. The Quantitative analysis of Chondroitin Sulfate Epitope and hyaluronan as Diagnostic Markers for Degenerative Joint diseases by ELISA Technique. Chiang mai University, 2000.
- (35) Hardingham T. Changes in chondroitin sulphate structure induced by joint disease. *Acta Orthop Scand Suppl* 1995; 266:107-110.
- (36) Laufer S. Osteoarthritis therapy--are there still unmet needs? *Rheumatology (Oxford)* 2004; 43 Suppl 1:i9-15.
- (37) The effects of glucosamine on human chondrocyte gene expression. Madrid, Spain: 1996.

- (38) Setnikar I PR. Pharmacokinetics of glucosamine in man. *Arzneimittelforschung/Drug Res* 43(II), 1109-1113. 1993.
- (39) Bucci L. Chondroprotective agents: Glucosamine salts and chondroitin sulfates. *Townsend Letter for Doctors*. 52-54. 1994.
- (40) Muller-Fassbender H eal. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. *Osteoarthritis Cartilage*. 2[61], 69. 1994.
- (41) Conte A eal. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. *Arzneimittelforschung/Drug Res* 45, 918-925. 1995.
- (42) Faculty of Pharmacy Mahidol University. Specification of Thai Medicinal Plants. Bangkok: Aksornsampan Press, 2004.
- (43) Thai Herbal Pharmacopoeia I. Prachachon . 1995. Bangkok.
- (44) Dechatiwongse T. Isolation of Constituents from the rhizomes of Plai (*Zingiber cassumunar* Roxb.). *Bull.Dept.Med.Sci*. 18[3], 75-79. 1976.
- (45) Pongprayoon U, Tuchinda P, Claeson P, et al. Topical antiinflammatory activity of DMPBD, a phenylbutanoid from *Zingiber cassumunar*. Part 2 hexane extractives. *Phytomedicine* 3[4], 323-326. 1997.
- (46) Pongprayoon U, Soontornsaratune P, Jarikasem S, et al. Topical antiinflammatory activity of the major lipophilic constituents of the rhizome of *Zingiber cassumunar*. Part 1 the essential oils. *Phytomedicine* 3[4], 319-322. 1997.

- (47) Wilkens R. Worldwide clinical safety with diclofenac. *Semin. Arthritis Rheum* 15 (suppl. 1), 105-110. 1985.
- (48) Kiatyingungsulee N, Wangmad M, Swasdimongkol D, Mokkahasmit M. Some pharmacological studies of active constituent in Plai (*Zingiber cassumunar* Roxb.). *Bull Dep Med Sci, Thailand* 21[1], 13-24. 2004.
- (49) Mokkahasmit M, Sawasdimongkol K, Sartravaha P. Toxicity study of some Thai medicinal plants. *Bull Dep Med Sci Thailand* 12[2], 36-65. 1971.
- (50) Panyathanya R, Ngamwathana W, Chawalidthumrong P. Study of acute and chronic toxicity of Plai (*Zingiber cassumunar* Roxb.) in rats. *Siriraj Hosp Gaz* 38, 413-416. 1986.
- (51) Habsah M, Amran M, Mackeen MM, Lajis NH, Kikuzaki H, Nakatani N et al. Screening of Zingiberaceae extracts for antimicrobial and antioxidant activities. *J Ethnopharmacol* 2000; 72(3):403-410.
- (52) Blumenkrantz N, Asboe-Hansen G. New method for quantitative determination of uronic acids. *Anal Biochem* 1973; 54(2):484-489.
- (53) Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. *Biochim Biophys Acta* 1986; 883(2):173-177.
- (54) Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976; 72:248-254.

- (55) Badger AM, Cook MN, Swift BA, Newman-Tarr TM, Gowen M, Lark M. Inhibition of interleukin-1-induced proteoglycan degradation and nitric oxide production in bovine articular cartilage/chondrocyte cultures by the natural product, hymenialdisine. *J Pharmacol Exp Ther* 1999; 290(2):587-593.
- (56) Goldring MB. Osteoarthritis and cartilage: the role of cytokines. *Curr Rheumatol Rep* 2000; 2(6):459-465.
- (57) Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. *Rheumatology (Oxford)* 2002; 41(9):972-980.
- (58) Yokoo T KM. Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. *Am J Physiol.* 270[1Pt 2], F123-F130. 1996.
- (59) Gordon DA, Klinkhoff AV. *Textbook of Rheumatology*. Philadelphia: WB Saunders, 2001.
- (60) Santana-Sahagun E, Weisman MH. *Textbook of Rheumatology*. Philadelphia: WB Saunder, 2001.
- (61) Brandt KD, Smith G, Kang SY, Myers S, O'Connor B, Albrecht M. Effects of diacerhein in an accelerated canine model of osteoarthritis. *Osteoarthritis Cartilage* 1997; 5(6):438-449.
- (62) Smith GN, Jr., Myers SL, Brandt KD, Mickler EA, Albrecht ME. Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. *Arthritis Rheum* 1999; 42(3):545-554.

- (63) Tamura T, Kosaka N, Ishiwa J, Sato T, Nagase H, Ito A. Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. *Osteoarthritis Cartilage* 2001; 9(3):257-263.
- (64) Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerhein and rheim on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. *J Rheumatol* 1998; 25(4):753-762.
- (65) Moore AR, Greenslade KJ, Alam CA, Willoughby DA. Effects of diacerhein on granuloma induced cartilage breakdown in the mouse. *Osteo Cart* 6[1], 19-23. 1998.
- (66) Takizawa M, Ohuchi E, Yamanaka H, Nakamura H, Ikeda E, Ghosh P et al. Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. *Arthritis Rheum* 2000; 43(4):812-820.
- (67) Felisaz N, Boumediene K, Ghayor C, Herrouin J-F, Bogdanowicz P. Stimulating effect of Diacerein on TGF-beta1 and beta2 expression in cartilage chondrocytes cultured with and without IL-1. *Osteo Cart* 7, 255-267. 1999.